Worth reading
62In focus
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
22.9
%Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPNet Sales85,654Millions of yenYear on year +4.7%Progress 21.9%
Operating profit6,076Millions of yenYear on year -22.9%Progress 17.9%
Ordinary income6,708Millions of yenYear on year -11.8%Progress 19.7%
Net income attributable to owners of the parent5,204Millions of yenYear on year +6.0%Progress 20.0%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥72.34
Financial position at period-end
Total assets577,945Millions of yen
of which net assets 301,952 Millions of yenEquity ratio 49.7%vs. prior year-end 0.0pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash and cash equivalents at end of period47,628 Millions of yen
Segment revenueChemical Products 24,688 Millions of yen (YoY -10.1%), Cement 16,052 Millions of yen (YoY -0.2%), Advanced Electronic Materials 22,303 Millions of yen (YoY +5.0%), Life Science 14,690 Millions of yen (YoY +61.5%), Environmental Business 1,094 Millions of yen (YoY -26.0%)
Segment profitChemical Products 523 Millions of yen (YoY -81.4%), Cement 2,551 Millions of yen (YoY +1.3%), Advanced Electronic Materials 3,126 Millions of yen (YoY +10.8%), Life Science 2,640 Millions of yen (YoY +54.8%), Environmental Business -7 Millions of yen
Outlook and shareholder returns
Full-year earnings forecast
Net Sales392,000 Millions of yen (YoY +12.2%)
Operating profit34,000 Millions of yen (YoY -8.2%)
Ordinary income34,000 Millions of yen (YoY -11.0%)
Net income26,000 Millions of yen (YoY +17.1%)
Revision to Earnings ForecastNet Sales To be determined → 392,000 Millions of yen / Operating profit To be determined → 34,000 Millions of yen / Ordinary income To be determined → 34,000 Millions of yen / Net income To be determined → 26,000 Millions of yen
Annual Dividend Forecast¥120 → ¥132（+10.0%）
Shareholder Return PolicyDOE of 4.0% (target for the final year of the Medium-Term Management Plan 2030)
Factors Behind Changes in Business Performance
Revenue increased due to the consolidation of the Tokuyama Life Science Group and increased sales of semiconductor-related products, despite a decline in chemical sales caused by a temporary shortage of raw materials. Operating income decreased due to lower chemical sales and higher raw material and fuel costs. Non-operating and extraordinary gains and losses improved, mainly due to an increase in gains on sales of investment securities resulting from a reduction in strategically held shares.
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 companies / Excluded 0 companies / Company name No applicable matters
Material subsequent eventsA transaction under which the domestic sales business for cement and solidifying materials and shares in certain consolidated subsidiaries will be transferred to a new company, after which the shares in the new company will be sold to TAIHEIYO CEMENT CORPORATION. The new company is scheduled to be established on 1 July 2026, the business separation is scheduled for 1 October 2026, and the sale price is scheduled to be ¥37,000 million.
Impairment lossNone recorded for the current fiscal year (-)
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets 11 Millions of yen, Gain on sale of investment securities 637 Millions of yen, Subsidy Income 51 Millions of yen / Extraordinary loss Loss on sale of fixed assets 0 Millions of yen, Losses on disposal of fixed assets 78 Millions of yen, Loss on sale of investment securities 7 Millions of yen
Depreciation and amortization5,751 Millions of yen
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End72,088,327
Treasury Shares at Period-End137,762
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | 85,654 Millions of yen (YoY +4.7%) |
| Operating profit | 6,076 Millions of yen (YoY -22.9%) |
| Ordinary income | 6,708 Millions of yen (YoY -11.8%) |
| Profit attributable to owners of the parent | 5,204 Millions of yen (YoY +6.0%) |
| Net income per share | ¥72.34 |
| Equity ratio | End of the current fiscal period 49.7% / End of previous period 49.7% |
| Total assets | 577,945 Millions of yen |
| Net assets | 301,952 Millions of yen |
| Cash and cash equivalents at end of period | 47,628 Millions of yen |
| Full-year earnings forecast | Net Sales 392,000 Millions of yen (YoY +12.2%) / Operating profit 34,000 Millions of yen (YoY -8.2%) / Ordinary income 34,000 Millions of yen (YoY -11.0%) / Net income 26,000 Millions of yen (YoY +17.1%) |
| Revision to Earnings Forecast | Net Sales To be determined → 392,000 Millions of yen / Operating profit To be determined → 34,000 Millions of yen / Ordinary income To be determined → 34,000 Millions of yen / Net income To be determined → 26,000 Millions of yen |
| Annual Dividend Forecast | ¥120 → ¥132（+10.0%） |
| Shareholder Return Policy | DOE of 4.0% (target for the final year of the Medium-Term Management Plan 2030) |
| Segment revenue | Chemical Products 24,688 Millions of yen (YoY -10.1%), Cement 16,052 Millions of yen (YoY -0.2%), Advanced Electronic Materials 22,303 Millions of yen (YoY +5.0%), Life Science 14,690 Millions of yen (YoY +61.5%), Environmental Business 1,094 Millions of yen (YoY -26.0%) |
| Segment profit | Chemical Products 523 Millions of yen (YoY -81.4%), Cement 2,551 Millions of yen (YoY +1.3%), Advanced Electronic Materials 3,126 Millions of yen (YoY +10.8%), Life Science 2,640 Millions of yen (YoY +54.8%), Environmental Business -7 Millions of yen |
| Depreciation and amortization | 5,751 Millions of yen |
| Impairment loss | None recorded for the current fiscal year (-) |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets 11 Millions of yen, Gain on sale of investment securities 637 Millions of yen, Subsidy Income 51 Millions of yen / Extraordinary loss Loss on sale of fixed assets 0 Millions of yen, Losses on disposal of fixed assets 78 Millions of yen, Loss on sale of investment securities 7 Millions of yen |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name No applicable matters |
| Material subsequent events | A transaction under which the domestic sales business for cement and solidifying materials and shares in certain consolidated subsidiaries will be transferred to a new company, after which the shares in the new company will be sold to TAIHEIYO CEMENT CORPORATION. The new company is scheduled to be established on 1 July 2026, the business separation is scheduled for 1 October 2026, and the sale price is scheduled to be ¥37,000 million. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 72,088,327 |
| Treasury Shares at Period-End | 137,762 |
| Factors Behind Changes in Business Performance | Revenue increased due to the consolidation of the Tokuyama Life Science Group and increased sales of semiconductor-related products, despite a decline in chemical sales caused by a temporary shortage of raw materials. Operating income decreased due to lower chemical sales and higher raw material and fuel costs. Non-operating and extraordinary gains and losses improved, mainly due to an increase in gains on sales of investment securities resulting from a reduction in strategically held shares. |
Items this document does not state (7)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesPayout ratioRegional salesOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased despite a decline in chemical sales caused by a temporary shortage of raw materials, primarily due to the consolidation of the Tokuyama Life Science Group and increased sales of semiconductor-related products. Operating income decreased due to lower chemical sales, higher raw material and fuel costs, and increases in selling, general and administrative expenses and logistics costs associated with the consolidation of the Tokuyama Life Science Group. The full-year earnings forecast and dividend forecast were disclosed in light of the recent business environment and earnings trends.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.